Pathway Labs
Is this your brand? Claim it — free, and takes a minute with your work email.
Overview
Tagline Brand's website · 2026-10-04
EchoNext turns the world's most common cardiac test (12-lead ECG) into an AI-driven biomarker without requiring new hardware or retraining staff, providing actionable insights for high-risk patients. It is supported by extensive peer-reviewed, prospectively validated research.
Description Brand's website · 2026-10-04
Pathway Labs offers EchoNext, an AI-powered platform that transforms standard 12-lead ECGs into a next-generation biomarker for early detection of structural heart disease. It aims to increase new clinically significant diagnoses and integrate seamlessly into existing healthcare workflows.
Offerings
Core capabilities Brand's website · 2026-10-04
- EchoNext
- an AI-powered platform that analyzes standard 12-lead ECGs to detect structural heart disease.
Pricing Brand's website · 2026-10-04
Not explicitly mentioned in the provided data.
Audience
Target industry Brand's website · 2026-10-04
Health systems, hospitals, and cardiology teams seeking early and efficient detection of structural heart disease.
Is this your business?
The information above is publicly sourced — assembled by Optimly from Pathway Labs's website and public pages.
Claim this profile to publish your own verified Business Profile and speak for Pathway Labs across the index.
Claim Pathway Labs — free →Page last updated 2026-10-17.